Related Experiment Video
Updated: Dec 1, 2025

06:52
Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
1.7K
The Coppery Age: Copper (Cu)-Involved Nanotheranostics
Caihong Dong1, Wei Feng2,3, Wenwen Xu4
1Department of Ultrasound Zhongshan Hospital Fudan University Shanghai 200032 P. R. China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|November 11, 2020
Summary
Copper (Cu) nanoplatforms show promise for advanced biomedical applications, leveraging copper
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Materials Science
Background:
- Copper (Cu) ions are essential trace elements with significant biological roles, including promoting angiogenesis and regulating metabolism.
- Advances in nanotechnology have led to the development of copper-involved biomaterial nanoplatforms with theranostic capabilities.
- These nanoplatforms harness the biological effects of copper species and the properties of copper nanoparticles.
Purpose of the Study:
- To review the principles, progress, and prospects of copper-composed functional nanoplatforms for biomedical applications.
- To discuss the design and construction of these nanoplatforms.
- To highlight diverse applications including nanomedicine, nanotherapeutics, antibacteria, tissue regeneration, and bioimaging.
Main Methods:
- Review of recent significant progress in copper-involved nanotheranostics.
- Discussion on the engineering of copper-based nanocomposites for synergistic nanotherapeutics.
- Analysis of biological effects and biosafety of these nanoplatforms.
Main Results:
- Copper-based nanoplatforms offer intriguing theranostic performances in biomedicine.
- Engineering of nanocomposites enables synergistic therapeutic effects.
- Biological effects and biosafety are crucial for clinical translation.
Conclusions:
- Copper-involved nanotherapeutic modalities are poised for broad biomedical applications in preclinical and clinical settings.
- Despite current research being in its infancy, the 'Copper Age' of nanotherapeutics is emerging.
- Further research is needed to address clinical concerns and hurdles for wider adoption.

